Published in Cancer on January 15, 2010
Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol (2013) 0.81
Neuro-oncology: gangliogliomas--what is the appropriate management strategy? Nat Rev Neurol (2010) 0.80
Anaplastic ganglioglioma: a report of three cases and review of the literature. J Neurooncol (2015) 0.78
The role of postoperative radiotherapy for the treatment of gangliogliomas. Cancer (2010) 0.78
Epilepsy due to a temporal ganglioglioma and its subsequent malignant transformation into a primitive neuroectodermal tumor. Surg Neurol Int (2012) 0.75
Bilateral internal auditory canal gangliogliomas mimicking neurofibromatosis Type II. Surg Neurol Int (2016) 0.75
Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database. Neuro Oncol (2017) 0.75
Genetic Characterization of a Multifocal Ganglioglioma Originating Within the Spinal Cord. World Neurosurg (2016) 0.75
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc (2008) 8.94
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol (2005) 3.86
Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol (2008) 2.83
Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol (2010) 2.71
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol (2009) 2.54
Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med (2006) 2.26
Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc (2007) 2.18
A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol (2008) 2.15
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. Lancet Neurol (2012) 1.93
Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol (2005) 1.77
Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol (2006) 1.76
Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer (2007) 1.73
Final results of a prospective study comparing the local control of short-course and long-course radiotherapy for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys (2010) 1.68
Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis. Int J Radiat Oncol Biol Phys (2008) 1.63
Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol (2010) 1.63
Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc (2007) 1.55
Elective Nodal Irradiation (ENI) doesn't appear to provide a clear benefit for patients with unresectable non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys (2008) 1.49
In regard to the radiotherapy of myxopapillary ependymomas. Int J Radiat Oncol Biol Phys (2002) 1.48
Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 1.45
Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis. Oral Oncol (2010) 1.40
The first score predicting overall survival in patients with metastatic spinal cord compression. Cancer (2008) 1.28
Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol (2005) 1.27
Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.27
A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer (2006) 1.26
Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience. J Surg Oncol (2002) 1.23
Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys (2002) 1.21
Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.18
Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer (2007) 1.17
Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol (2010) 1.16
Central neurocytoma: management recommendations based on a 35-year experience. Int J Radiat Oncol Biol Phys (2006) 1.16
Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer (2009) 1.15
Dose escalation of radiotherapy for metastatic spinal cord compression (MSCC) in patients with relatively favorable survival prognosis. Strahlenther Onkol (2011) 1.14
Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol (2009) 1.12
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol (2012) 1.12
Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: results of a matched pair analysis. Eur J Cancer (2008) 1.11
Breast cancer-related lymphedema. Mayo Clin Proc (2005) 1.11
Re: Proton vs intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst (2013) 1.10
Treatment of atypical neurocytomas. Cancer (2004) 1.09
Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys (2009) 1.09
Locally advanced stage IV squamous cell carcinoma of the head and neck: impact of pre-radiotherapy hemoglobin level and interruptions during radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.08
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol (2005) 1.07
Prognostic factors for outcomes after whole-brain irradiation of brain metastases from relatively radioresistant tumors: a retrospective analysis. BMC Cancer (2010) 1.06
Matched pair analysis comparing surgery followed by radiotherapy and radiotherapy alone for metastatic spinal cord compression. J Clin Oncol (2010) 1.06
Scoring systems to estimate intracerebral control and survival rates of patients irradiated for brain metastases. Int J Radiat Oncol Biol Phys (2010) 1.05
Surgery followed by radiotherapy versus radiotherapy alone for metastatic spinal cord compression from unfavorable tumors. Int J Radiat Oncol Biol Phys (2011) 1.04
Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: results from a prospective, randomized sham-controlled trial. Mov Disord (2008) 1.03
Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. Cancer (2010) 1.02
Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. J Thorac Oncol (2007) 1.01
Therapy of meningeal melanocytomas. Cancer (2004) 1.01
Lung cancer in the elderly. J Clin Oncol (2007) 1.00
Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. Cancer (2007) 0.99
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.99
Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. Cancer (2009) 0.99
Comparison of stereotactic radiosurgery (SRS) alone and whole brain radiotherapy (WBRT) plus a stereotactic boost (WBRT+SRS) for one to three brain metastases. Strahlenther Onkol (2008) 0.99
Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer (2011) 0.98
A new survival score for patients with brain metastases who received whole-brain radiotherapy (WBRT) alone. Radiother Oncol (2013) 0.98
A score predicting posttreatment ambulatory status in patients irradiated for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys (2008) 0.98
Treatment of painful bone metastases. Nat Rev Clin Oncol (2010) 0.98
Multiphoton excitation fluorescence microscopy of 5-aminolevulinic acid induced fluorescence in experimental gliomas. Lasers Surg Med (2008) 0.98
A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer (2012) 0.98
Prognostic value of the MIB-1 labeling index for central neurocytomas. Neurology (2004) 0.97
Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol (2006) 0.97
The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer (2011) 0.97
Dose-response relationship for fractionated irradiation in the treatment of spinal meningeal melanocytomas: a review of the literature. J Neurooncol (2005) 0.96
Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol (2003) 0.96
Imaging of brain and brain tumor specimens by time-resolved multiphoton excitation microscopy ex vivo. Neuro Oncol (2007) 0.96
Pallidal stimulation for dystonia. Neurosurgery (2004) 0.96
Preliminary results of spinal cord compression recurrence evaluation (score-1) study comparing short-course versus long-course radiotherapy for local control of malignant epidural spinal cord compression. Int J Radiat Oncol Biol Phys (2008) 0.96
Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. Cancer (2007) 0.95
Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck. Strahlenther Onkol (2009) 0.95
Chronic inhibition of the subthalamic nucleus in Parkinson's disease. J Neurol Sci (2004) 0.94
A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer (2007) 0.94
Prognostic factors affecting locally recurrent rectal cancer and clinical significance of hemoglobin. Int J Radiat Oncol Biol Phys (2007) 0.94
A score to identify patients with metastatic spinal cord compression who may be candidates for best supportive care. Cancer (2012) 0.93
Is improvement in the quality of life after subthalamic nucleus stimulation in Parkinson's disease predictable? Mov Disord (2011) 0.92
Evaluation of B7-H3 expression as a biomarker of biochemical recurrence after salvage radiation therapy for recurrent prostate cancer. Int J Radiat Oncol Biol Phys (2010) 0.92
Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol (2007) 0.92
Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. Cancer (2007) 0.92
Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease. Mov Disord (2010) 0.92